Tests stopping or continuing hepatitis B antiviral drugs in chronic hepatitis B patients
Compares stopping versus continuing long-term antiviral drugs in people with chronic hepatitis B.
Plain-language title generated from the registry record
Registry title: Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)
Key facts
- Where
- Hong Kong, Hong KongSee the site
- Phase
- Phase 4
Where in Hong Kong
- Humanity & Health Research CentreHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Humanity & Health Medical Group Limited
- Trial code
- NCT03792919
- Record updated
- 24 March 2025
- Original description
To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.Read full original descriptionShow less
Virological Response After Cessation of Long Term Anti-HBV Nucleos(t)Ide Analogues (NAs) vs. Keeping on NAs Among Chronic Hepatitis B (CHB) Patients
To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.
Inclusion: HBsAg positive, HBeAg negative, antibody to HBeAg-positive; Stable administration of anti-HBV neucleos(t)ides analogue mono therapy for at least more than one and a half year; Demonstration of undetectable HBV DNA on three occasions, each at least 6 months apart, which is consistent with the APASL stopping rule; Patients read, understand the consent form, and signed the study consent.
Exclusion: Patient with concurrent hepatitis viruses or HIV infection; Patient with other liver diseases; Patients are reluctant to stop their anti-HBV treatment.